Biogen To Pay $1.25B For Forward Pharma's MS Drug IP
Biogen Inc. on Tuesday agreed to pay $1.25 billion to Forward Pharma A/S so it can license all of the Danish company's intellectual property, as the two companies continue to battle...To view the full article, register now.
Already a subscriber? Click here to view full article